What does sermorelin actually do?
Sermorelin acetate is a synthetic analog of endogenous growth hormone releasing hormone (GHRH), specifically the first 29 amino acids of the 44-amino-acid native peptide. It binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating those cells to produce and release growth hormone (GH).
The key distinction from exogenous GH therapy: sermorelin stimulates the pituitary to produce its own GH through a pulse pattern that more closely mirrors natural physiology. Exogenous GH bypasses the pituitary entirely and delivers GH directly. This has implications for how the downstream hormone cascade unfolds, including feedback regulation.
Once GH is released, it travels to the liver and other tissues where it stimulates production of insulin-like growth factor 1 (IGF-1). IGF-1 is the primary mediator of many of GH’s downstream effects on body composition, cellular metabolism, and tissue maintenance.
How does the GH-IGF-1 axis connect to testosterone production?
The connection between growth hormone, IGF-1, and testosterone is established at the cellular level. Here is how the pathway works:
IGF-1 receptors on Leydig cells
Leydig cells in the testes are the primary site of testosterone biosynthesis in men. These cells express IGF-1 receptors. Research in both animal models and human tissue has demonstrated that IGF-1 can directly stimulate Leydig cell steroidogenesis — the biochemical process by which cholesterol is converted into testosterone and other androgens.
This means that when sermorelin raises GH, and GH raises IGF-1, the increased IGF-1 may support testicular testosterone production through direct receptor signaling on Leydig cells. The effect is indirect and dependent on the magnitude of IGF-1 elevation, but it is not speculative — it reflects known receptor biology.
GH acts at the hypothalamic-pituitary level too
Growth hormone also appears to modulate the hypothalamic-pituitary-gonadal (HPG) axis at higher regulatory levels. GH receptors are present in the hypothalamus and pituitary, and GH signaling can influence gonadotropin releasing hormone (GnRH) pulsatility and LH secretion — the upstream signals that tell the testes to produce testosterone.
In states of significant GH deficiency, LH pulsatility and testicular responsiveness are often impaired. Restoring GH levels toward the normal range may partially restore the sensitivity of this axis, particularly in men whose suboptimal testosterone is downstream of impaired GH secretion rather than primary testicular failure.
Body composition effects create additional hormonal benefits
Adipose tissue — particularly visceral fat — is metabolically active in ways that suppress testosterone. Visceral fat produces aromatase, the enzyme that converts testosterone to estradiol, and produces inflammatory cytokines that inhibit testicular function. Sermorelin’s well-documented effects on body composition (supporting lean mass, reducing fat mass) may therefore support testosterone levels indirectly through the adipose-endocrine connection, independent of any direct GH-IGF-1-Leydig mechanism.
Sermorelin can support testosterone indirectly through the GH–IGF-1 axis, but it is not a testosterone therapy and does not replace TRT.
What does the evidence say about sermorelin and testosterone?
The mechanistic basis for sermorelin supporting testosterone is sound. The evidentiary picture on the magnitude of the effect in clinical populations is more nuanced:
- Men with GH deficiency: In men with documented GH deficiency, GH replacement has been associated with improvements in testosterone, likely through the IGF-1 and HPG axis mechanisms described above. The effect is most pronounced when GH deficiency is the primary driver of the hormonal picture.
- Healthy aging men with declining GH: GH secretion declines with age — this is well established. Whether sermorelin in this population produces meaningful testosterone increases is less clearly established. Some patients and clinicians report improved testosterone on labs, others see minimal change. Individual variation is real and influenced by the degree of underlying GH insufficiency, age, body composition, and other hormonal factors.
- Not a substitute for TRT: For men with primary hypogonadism (testicular failure) or significantly low testosterone from non-GH causes, sermorelin will not address the core deficit. Clinical evaluation must distinguish the origin of low testosterone before selecting a treatment approach.
What does a clinical evaluation look like before starting sermorelin?
Because the GH-testosterone relationship is indirect and individual-dependent, a clinician evaluation before starting sermorelin includes:
- Baseline labs:Total testosterone, free testosterone, IGF-1, LH, FSH, and SHBG. These establish where in the hormone axis the patient’s picture sits.
- Symptom review: Low energy, poor body composition, reduced libido, and sleep quality issues can reflect suboptimal GH, suboptimal testosterone, or both. Separating the contributions requires the labs.
- Follow-up monitoring: IGF-1 is the primary sermorelin efficacy marker. Testosterone trends are monitored alongside it in men with relevant baseline concerns.
A clinician who reviews your specific lab pattern and symptom picture is the right resource for whether sermorelin — alone or alongside other therapies — is appropriate for you.
Frequently asked questions
Does sermorelin increase testosterone?
Sermorelin stimulates growth hormone release, which raises IGF-1. IGF-1 receptors are present on Leydig cells in the testes, which are the cells responsible for testosterone production. Animal and human data suggest the GH-IGF-1 axis can support gonadal steroidogenesis, meaning sermorelin may indirectly support testosterone levels — particularly in men with suboptimal GH secretion. It is not a testosterone therapy and does not replace TRT when testosterone deficiency is the primary issue.
How long does sermorelin take to affect testosterone?
Sermorelin works upstream through the GH-IGF-1 axis, which means any downstream effect on testosterone is indirect and takes time. IGF-1 levels typically take 4–8 weeks to respond meaningfully to sermorelin. Any downstream hormonal effects, including on testosterone, follow a similar or longer timeline. Clinical monitoring at 8–12 weeks is standard.
Is sermorelin the same as testosterone therapy?
No. Sermorelin is a growth hormone releasing hormone (GHRH) analog that stimulates the pituitary to release growth hormone. Testosterone replacement therapy (TRT) directly supplements testosterone levels. They address different axes and have different clinical profiles, indications, and monitoring requirements.
Can sermorelin help with low testosterone symptoms?
Some symptoms associated with suboptimal testosterone — low energy, poor body composition, reduced libido — also occur with suboptimal growth hormone secretion. Sermorelin may support those overlapping symptoms through the GH-IGF-1 axis. Whether a patient's symptom picture is primarily GH-related, testosterone-related, or both requires clinical evaluation, not self-assessment.
Who prescribes sermorelin?
Licensed clinicians — typically those with training in hormone optimization, anti-aging medicine, or endocrinology — prescribe sermorelin after reviewing labs, health history, and symptoms. Sermorelin is compounded by licensed 503A pharmacies and requires a valid prescription.
Is sermorelin FDA-approved?
Sermorelin acetate was previously available as an FDA-approved drug (Geref). That brand has been discontinued. Sermorelin compounded by licensed 503A pharmacies is legal under current compounding rules. It is not an FDA-approved drug in its compounded form — clinicians prescribe it as a compounded medication for specific patients with individualized clinical need.